Several lines of evidence point to an important role and great therapeutic potential of the ligand sensing transcription factor Nurr1 in AD, PD, and MS but pharmacological validation and exploitation of Nurr1 as therapeutic target is pending. The gene discussed is NR4A2; the disease is myeloid sarcoma.